摘要
目的探讨法舒地尔联合阿托伐他汀治疗对慢性阻塞性肺疾病(COPD)合并肺动脉高压患者炎性因子、肺功能及心室重构的影响。方法2018年5月至2020年5月在我院接受治疗的89例COPD合并肺动脉高压患者,根据药物治疗方案不同,分为研究组46例(法舒地尔联合阿托伐他汀治疗)和对照组43例(阿托伐他汀治疗)。比较两组临床疗效、炎性因子水平、肺循环、肺功能、心室重构及不良反应。结果研究组总有效率高于对照组(P<0.05);与治疗前相比,治疗后两组C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)、平均肺动脉压(MPAP)、收缩末期升主动脉根部内径(AO)及右室舒张末内径(RVDD)降低,1秒用力呼气容积(FEV_1)、1秒用力呼气容积占用力肺活量的百分比(FEV_1/FVC)、三尖瓣最大反流速度(TRVmax)、右室射血分数(RVEF)、右室心肌质量指数(RVMI)均上升,且研究组变化更显著(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论法舒地尔联合阿托伐他汀治疗COPD合并肺动脉高压患者疗效确切,可有效调节患者炎性因子水平,降低肺动脉压,改善肺功能,并抑制心室重构,且安全性高,值得临床应用推广。
Objective To explore the effect of fasudil combined with atorvastatin on inflammatory factors,lung function and ventricular remodeling in patients with chronic obstructive pulmonary disease( COPD) combined with pulmonary hypertension.Methods Eighty-nine patients with COPD and pulmonary hypertension treated in our hospital from May 2018 to May 2020 were involved in the study.The patients were divided into a study group( n = 46) and a control group( n = 43) according to the different drug treatment plans.The study group was treated with fasudil combined with atorvastatin.The control group was treated with atorvastatin alone.The clinical efficacy and levels of inflammatory factors,pulmonary circulation,lung function,ventricular remodeling,and adverse reactions were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group( P<0. 05). Compared with those before treatment,C-reactive protein( CRP),tumor necrosis factor-α( TNF-α),interleukin-8( IL-8),mean pulmonary artery pressure( MPAP),end systolic ascending aortic root diameter( AO) and right ventricular end diastolic diameter( RVDD) were decreased in the two groups after treatment while the 1 second forced expiratory volume( FEV1),percentage of forced vital capacity occupied by forced expiratory volume in 1 second( FEV1/FVC),maximum tricuspid regurgitation velocity( TRVmax),right ventricular ejection fraction( RVEF),and right ventricular myocardial mass index( RVMI) were all increased,and the study group was the most significant( P<0. 05).There was no difference in the incidence of adverse reactions between the two groups( P>0. 05). Conclusion Fasudil combined with atorvastatin has a definite curative effect in the treatment of patients with COPD and pulmonary hypertension.It can effectively regulate the level of inflammatory factors,reduce the pulmonary artery pressure,improve the lung function,and inhibit the ventricular remodeling.It has a high safety and is worthy of clinical application and promotion.
作者
买迪娜·阿布都瓦衣提
祖里培亚·艾拜都拉
麦丽开·库尔班
ABuDouWayiTi·MaiDiNa;AiB aiDouLa·ZuLiPeiYa;KuErBan·MaLiKa(Xinjiang Uygur Autonomous Region People’s Hospital,Urumqi 830000,China)
出处
《实用医院临床杂志》
2021年第6期39-43,共5页
Practical Journal of Clinical Medicine
基金
新疆维吾尔自治区自然科学基金(编号:2018D01C015)。
